Understanding Your Diagnosis: CTLA4 Haploinsufficiency (CHAI)

Receiving a diagnosis of CTLA4 haploinsufficiency (also known as CHAI) often brings a mix of relief and new questions. For many families, this diagnosis follows a long and exhausting search for answers. Research from specific clinical cohorts indicates a median delay of approximately 8 years from the first symptom to a definitive genetic diagnosis ^[1]. During this “diagnostic odyssey,” you may have been given other labels such as Common Variable Immunodeficiency (CVID), Autoimmune Lymphoproliferative Syndrome (ALPS), or Inflammatory Bowel Disease (IBD) ^[2][3][4]. Understanding that this is a recognized genetic condition can be an important step in navigating your care.

The Immune System’s ‘Brakes’

To understand CHAI, it helps to think of your immune system like a car. A healthy immune system has an “accelerator” to speed up when it needs to fight germs and “brakes” to slow down so it doesn’t cause damage. The CTLA-4 protein acts as one of the most important brakes in this system to regulate immune activation ^[5].

In CHAI, you have one working copy of the CTLA4 gene instead of two (this is what haploinsufficiency means). Because there isn’t enough of the brake protein, the immune system can experience dysregulation and stay “on” when it should be “off” ^[6][7].

The Dual Paradox

This lack of control creates a confusing situation where the immune system is both overactive and underactive at the same time:

• Autoimmunity (Overactive): Without enough brakes, immune cells can attack your own body. This often shows up as autoimmune cytopenias (low blood counts because the body is destroying its own blood cells), enteropathy (chronic diarrhea or gut inflammation), or lymphoproliferation (swollen lymph nodes and spleen) ^[8].
• Immunodeficiency (Underactive): Paradoxically, the same lack of control makes it harder for the body to produce the right antibodies to fight external germs. This is called hypogammaglobulinemia (low antibody levels), which was reported in 84% of affected people in one large international cohort ^[8].

Understanding Incomplete Penetrance

One of the most complex parts of CHAI is that the same genetic variant can look very different from person to person, even within the same family. This is called incomplete penetrance.

Cohort studies estimate that about 67% to 71% of people who carry a pathogenic genetic variant will develop symptoms during their lifetime ^[8][9]. Please note these are cohort-dependent estimates. This means:

• A parent may carry the gene but have no symptoms at all or only very mild ones (a 50% chance of inheriting a variant is not a 50% chance of developing disease).
• A child or sibling with the exact same gene variant could be more severely affected.
• The age when symptoms first appear can vary widely. While the median age for symptoms to start in one cohort was around 11 years old, some people do not show signs of the condition until they are as old as 50 ^[8][1].

Because the condition is so variable, it is often recommended that family members of a diagnosed person undergo genetic counseling before predictive testing is pursued, even if they currently feel well ^[10].

Common Clinical Features

CHAI is a multi-system condition, meaning it can affect different parts of the body. In a worldwide group of patients, researchers found several common patterns of involvement:

• Digestive System (59%): Chronic diarrhea and inflammation in the gut ^[8].
• Respiratory System (68%): Recurrent infections or specialized lung inflammation called GLILD (Granulomatous-Lymphocytic Interstitial Lung Disease) ^[8][11].
• Neurological System (21-29%): Headaches, seizures, or inflammation in the brain and spine ^[8][12].
• Blood and Lymph Nodes: High rates of low blood counts (62%) and enlarged lymph nodes (73%) ^[8].

Your medical team will use this information to create an individualized monitoring plan tailored to your specific symptoms and genetic profile. Finding the right specialist—typically a clinical immunologist with experience in immune dysregulation—is the best way to manage the complexities of this diagnosis.